Cost-effectiveness of a new combined immunosuppressive and anti-infectious regimen in kidney transplantation

International Journal of Technology Assessment in Health Care

Volumn 24, Issue 3, 2008, Pages 312-317

  Wasserfallen, Jean Blaise ^a,b   Kast Brückner, Mira ^a,b   Manuel, Oriol ^a,b   Venetz, Jean Pierre ^a,b   Meylan, Pascal R A ^a,b   Pascual, Manuel ^b  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

CMV infection; Cost effectiveness; Graft rejection; Immunosuppression; Kidney transplantation

Indexed keywords

ACCOUNTING SYSTEMS; KIDNEY TRANSPLANTATION;

ANTIVIRUS AGENT; AZATHIOPRINE; BASILIXIMAB; CORTICOSTEROID; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; VALACICLOVIR; VALGANCICLOVIR;

ADULT; ARTICLE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; CYTOMEGALOVIRUS INFECTION; FEMALE; HEALTH CARE COST; HUMAN; INFECTIOUS COMPLICATION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PROPHYLAXIS; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS; SWITZERLAND; UNIVERSITY HOSPITAL;

ADULT; ANTI-INFECTIVE AGENTS; COST-BENEFIT ANALYSIS; DRUG THERAPY, COMBINATION; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SWITZERLAND;

EID: 46749146188     PISSN: 02664623     EISSN: 14716348     Source Type: Journal    
DOI: 10.1017/S0266462308080410     Document Type: Article

References (23)

1. Alangaden GJ, Thyagarajan R, Gruber SA, et al. Infectious complications after kidney transplantation: Current epidemiology and associated risk factors. Clin Transplant. 2006;20:401-409.
2. Craig AM, McKechnie T, McKenna M, et al. A Cost-effectiveness analysis of tacrolimus versus Cciclosporine microemulsion following kidney transplantation. Transplant Proc. 2002;34:1646-1648.
3. Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med. 1998;338:1741-1751.
4. Gane E, Saliba F, Valdecasas GJ, et al. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected]. Lancet. 1997;350:1729-1733.
5. Hagenmeyer E, Häussler B, Hempel E, et al. Resource use and treatment costs after kidney transplantation. Impact of demographic factors, comorbidities, and complications. Transplantation. 2004;77:1545-1550.
6. Hardinger KL, Bohl DL, Schnitzler MA, et al. A randomized, prospective, pharmacoeconomic trial of tacrolimus versus cyclosporine in combination with thymoglobulin in kidney transplant recipients. Transplantation. 2005;80:41-46.
7. Hart GD, Paya CV. Prophylaxis for CMV should now replace preemptive therapy in solid organ transplantation. Rev Med Virol. 2001;11:73-81.
8. Khoury JA, Storch GA, Bohl DL, et al. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant. 2006;6:2134-2143.
9. Koetz A, Delbruck R, Furtwangler A, et al. Cytomegalovirus pp65 antigen-guided preemptive therapy with ganciclovir in solid organ transplant recipients: A prospective, double-blind, placebo-controlled study. Transplantation. 2001;72:1325-1327.
10. Lazzaro C, McKechnie T, McKenna M. Tacrolimus versus ciclosporin in renal transplantation in Italy: Cost-minimization and cost-effectiveness analyses. J Nephrol. 2002;15:580-588.
11. Legendre CM, Norman DJ, Keating MR, et al. Valaciclovir prophylaxis of cytomegalovirus infection and disease in renal transplantation: An economic evaluation. Transplantation. 2000;70:1463-1468.
12. Magee C, Pascual M. Update in renal transplantation. Arch Intern Med. 2004;164:1373-1388.
13. Manuel O, Venetz JP, Fellay J, et al. Efficacy and safety of universal valganciclovir prophylaxis combined with a tacrolimus/ mycophenolate based regimen in kidney transplantation. Swiss Med Wkly. 2007;137:669-676.
14. Mauskopf JA, Richter A, Annemans L, et al. Cost-effectiveness model of cytomegalovirusmanagement strategies in renal transplantation. Comparing valaciclovir prophylaxis with current practice. Pharmacoeconomics. 2000;18:239-251.
15. Morris-Stiff G, Richards T, Singh J, et al. Pharmaco-economic study of FK 506 (Prograf) and cyclosporin A Neoral in cadaveric renal transplantation. Transplant Proc. 1998;30:1285-1286.
16. Muheim C, Vogel G, Seydoux C, et al. Determinants of protracted cytomegalovirus infection in solid-organ transplant patients. Transplantation. 2002;74:226-236.
17. Nett PC, Heisey DM, Fernandez LA, et al. Association of cytomegalovirus disease and acute rejection with graft loss in kidney transplantation. Transplantation. 2004;78:1036-1041.
18. Offermann G. Immunosuppression for long-term maintenance of renal allograft function. Drugs. 2004;64:1325-1338.
19. Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir versus oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant. 2004;4:611-620.
20. Snydman DR. The case for cytomegalovirus prophylaxis in solid organ transplantation. Rev Med Virol. 2006;16:289-295.
21. Swiss drug compendium. Morant J, Ruppanner H, eds. 27th ed, Documed, Basel, 2006. http://www.kompendium.ch. Accessed 6 December 2007.
22. Tarmed. Swiss medical tariff. http://www.tarmed.ch. Accessed 6 December 2007.
23. Webster AC, Woodroffe RC, Taylor RS, Chapman JR, Craig JC. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplantation recipients: Meta-analysis and meta-regression of randomised trial data. BMJ. 2005;331;810.